NBIX vs SPOK · P/E 45, rev $1.77B vs P/E 17, rev $68.2M
Neurocrine Biosciences Inc (NBIX) versus Spok Holdings Inc (SPOK) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Spok Holdings Inc (SPOK) is a health information services company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SPOK revenue for 2026-06-30 was $68.2M. Net income was $6.1M. SPOK currently screens at market cap $215.3M and trailing P/E 17.5.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SPOK currently screens at market cap $215.3M and trailing P/E 17.5.
Not investment advice. Open the NBIX and SPOK stock pages for the full models.
Not investment advice.